Morphological and immunohistochemical validation personalized patient-derived xenograft model of non-small cellular lung cancer
A. A. Epishkina,
O. N. Deryabina,
O. N. Tumutolova,
D. S. Blinov,
A. A. Makhrova,
G. V. Brykin,
D. N. Shimanovskii,
E. V. Blinova https://doi.org/10.18499/2225-7357-2022-11-4-53-57
Abstract
The aim of the study was to carry out a comparative morphological and immunohistochemical analysis of peripheral non-small cell lung cancer, which served as a source of a xenograft tumor, and tissues of the third generation of a tumor that developed in animals.
Material and methods. We used 19 athymic BALB/c nu/nu mice, which were intraperitoneally injected with 1×106 CD8+ after sublethal irradiation in accordance with the humanization protocol. The transplantation of a tumor obtained from a 64-year-old patient was carried out three times consecutively. Samples of the original and xenograft tumors were automatically stained with hematoxylin and eosin, rabbit anti-CK7, anti-TTF, and anti-Ki67 antibodies. The evaluation of histological samples was carried out in accordance with the WHO recommendations (2015).
Results. It has been established that a third-generation tumor developing in the body of athymic humanized mice retains the morphological and immunohistochemical features of the patient's original tumor. The described approach may be used in preclinical and personalized studies in fundamental pharmacology and molecular oncology.
Supporting agencies: The study was supported by the grant of the President of the Russian Federation NSh-843.2022.3 (agreement No. 075-15-2022-842 dated May 12, 2022).
About the Authors
A. A. Epishkina
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Anna A. Epishkina – P.G. stud. of operative surgery and topographic anatomy department
ul. Bol'shaya Pirogovskaya, 2, str. 4, Moscow, 119435
O. N. Deryabina
Ogarev National Research Mordovia State University
Russian Federation
Russian Federation
Ol'ga N. Deryabina – Cand. Med. Sci., Assoc. Prof.
Saransk
O. N. Tumutolova
Ogarev National Research Mordovia State University
Russian Federation
Russian Federation
Oksana N. Tumutolova – Cand. Med. Sci., Assoc. Prof.
Saransk
D. S. Blinov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
Russian Federation
Russian Federation
Dmitrii S. Blinov – Doct. Med. Sci., Assoc. Prof.
Moscow
A. A. Makhrova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
Russian Federation
Russian Federation
Anna A. Makhrova
Moscow
G. V. Brykin
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Gordei V. Brykin – student
Moscow
D. N. Shimanovskii
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Denis N. Shimanovskii – student
Moscow
E. V. Blinova
I. M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Ekaterina V. Blinova – Doct. Med. Sci., Prof.
Moscow
References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: A Cancer Journal for Clinicians. 2019 Jan;69(1):7–34. doi: 10.3322/caac.21551
2. Dong Q, Chen ES, Zhao C, Jin C. Host-Microbiome Interaction in Lung Cancer. Frontiers in Immunology. 2021 May 24;12. doi: 10.3389/fimmu.2021.679829
3. Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nature Genetics. 2016 May 9;48(6):607–16. doi: 10.1038/ng.3564
4. Kim M, Mun H, Sung CO, Cho EJ, Jeon H-J, Chun S-M, et al. Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. Nature Communications. 2019 Sep 5;10(1):3991. doi: 10.1038/s41467-019-11867-6
5. Chijiwa T, Kawai K, Noguchi A, Sato H, Hayashi A, Cho H, et al. Establishment of patient-derived cancer xenografts in immunodeficient NOG mice. International Journal of Oncology. 2015 May 11;47(1):61–70. doi: 10.3892/ijo.2015.2997
6. Morton CL, Houghton PJ. Establishment of human tumor xenografts in immunodeficient mice. Nature Protocols. 2007 Feb;2(2):247–50. doi: 10.1038/nprot.2007.25
7. Blinov D, Blinova E, Dudina M, Suslova I, Samishina E, Roshchin D. Novel aminochromone derivative inhibits tumor growth on xenograft model of lung cancer in mice. Journal of Advanced Pharmaceutical Technology & Research. 2018;9(4):130–4. doi: 10.4103/japtr.japtr_313_18
8. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018 Jan;553(7689):446–54. doi: 10.1038/nature25183
9. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2018 Sep 12;68(6):394–424. doi: 10.3322/caac.21492
Review
For citations:
Epishkina A.A., Deryabina O.N., Tumutolova O.N., Blinov D.S., Makhrova A.A., Brykin G.V., Shimanovskii D.N., Blinova E.V. Morphological and immunohistochemical validation personalized patient-derived xenograft model of non-small cellular lung cancer. Journal of Anatomy and Histopathology. 2022;11(4):53-57. (In Russ.) https://doi.org/10.18499/2225-7357-2022-11-4-53-57
Views:
397
Email this article 